This excerpt taken from the ELN 20-F filed Feb 28, 2007.
In 2006, we entered into a collaboration with Transition to develop a small molecule approach to the treatment of mild to moderate Alzheimers disease. The molecule is a beta-amyloid anti-aggregate. Based upon pre-clinical data, by blocking the aggregation of amyloid beta, clearance of amyloid occurs and plaque build up is prevented.
Daily oral treatment with this compound has been shown to prevent cognition decline in a transgenic mouse model of Alzheimers disease, with reduced amyloid plaque load in the brain accompanied with an increased survival rate of these animals.
In 2006, three Phase 1 Single Ascending Dose studies were conducted by Transition showing that AZD-103/ELND-005 has a favorable pharmacokinetic profile and is safe and well tolerated. No significant drug-related adverse events have been reported to date.
In 2007, we will conduct additional clinical and non-clinical studies to support the initiation of a Phase 2 trial, targeted for 2007. This Phase 2 study will be a randomized, double-blind, placebo-controlled, dose-ranging study in mild to moderate Alzheimers disease patients.